
Collaborative Drug Discovery (CDD Vault) CEO is transforming humanitarian & commercial drug discovery...one collaboration at a time. clubhouse: @barrybunin
Burlingame, CA
Joined March 2009
- Tweets6.3K
- Following5.6K
- Followers1.5K
- Likes2.5K
Pinned Tweet
CDD Vault Update: Integrating Lilly TuneLab Small Molecule and Antibody Predictive Models in CDD Vault collaborativedrug.com/cdd-bl…
Barry Bunin retweeted
students should be able to recognize the most common drug structures and guess at least some of the relevant information like drug class, indication, or target class. this is just pattern recognition. here are the most common chemotypes.
Microsoft AI Chief: AI Is Not Conscious and We Should Keep It That Way - Business Insider businessinsider.com/mustafa-…
Barry Bunin retweeted
Great to see teams using the Boltz API at the Ebolathon successfully designing novel molecules! 140 molecules tested, 11 selective hits in Ebola pseudovirus assays. Exciting to see hackathon ideas turn into experimental results! 🧪 muni.bio/research/hits-from-…
Can AI Make Sense of Your Drug Discovery Data? collaborativedrug.com/cdd-bl…
Genetic variants shape single-cell chromatin accessibility and disease risk | Nature nature.com/articles/s41586-0…
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial | Eli Lilly and Company investor.lilly.com/news-rele…
Barry Bunin retweeted
Out and about recently. Randomly stumbled across someone with a Nobel in their backpack
If you look closely enough, breakthroughs in everything are accelerating exponentially.
An exponential always starts off looking small.
this might be my last normal tweet before biotech goes vertical
i'm not a whistleblower. I don't work at Lilly, Novo or any of the big labs
but there is a massive shift happening in human biology right now.
it's sitting in press releases and almost nobody reads them
the last 6 months alone:
- a once-daily pill roughly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.6 months)
- a one-time gene editing infusion cut hereditary angioedema attacks 87%, and 62% of patients stayed attack-free and off all other prevention for 6 months
- a one-time gene edit for cholesterol dropped LDL up to 62%, and it held for over a year
- a personalized mrna vaccine beat keytruda alone in a 1,137 patient melanoma phase 3
- retatrutide hit ~28% weight loss in a phase 3
- an ai-designed drug entered phase 3
- a pill that regrows hair passed its second phase 3
- an immunotherapy that could let some rectal cancer patients skip surgery, chemo and radiation just got fda approved
- a man lived 271 days off dialysis on a pig kidney
- human cells were caught passing chromosome-sized chunks of DNA to their neighbors, and it changes how the neighbors behave
we are on the verge of an era where the human body is a software problem and the update cycle gets shorter everyday
stick around, it's going to get weird
bio/acc
MCT1-dependent mitochondrial lactate import sustains cardiac metabolism | Nature nature.com/articles/s41586-0…
FY27 Q1 - Press Releases - Investor Relations - Microsoft microsoft.com/en-us/investor…
Webinar Recording: Federated Learning in Drug Discovery — How Lilly TuneLab Integrates with CDD Vault collaborativedrug.com/cdd-bl…
Barry Bunin retweeted
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
CDD Vault Update (October #2 2026): Search Table Plot Carousel, ELN Stoichiometry In-line Editing and Customization collaborativedrug.com/cdd-bl…
Anthropic files for IPO, setting the stage for a wave of new wealth in SF | The San Francisco Standard sfstandard.com/2026/10/26/an…
38% Silver Diamine Fluoride Stops Cavities in Kids Without Drilling inkorr.com/en/vceni-pidtverd…
Barry Bunin retweeted
JUST IN: A California space startup has illuminated a section of desert near Mount Whitney at night, demonstrating how future satellites could deliver sunlight to Earth on demand.
Reflect Orbital conducted the October 10 test using powerful ground-based spotlights to simulate sunlight redirected from orbit by large reflective mirrors.
Working with China Lake Mountain Rescue, the company illuminated terrain across roughly three miles, allowing rescue teams to conduct nighttime searches, stretcher carries and other emergency-response exercises.
Reflect Orbital ultimately wants to deploy satellites capable of directing sunlight toward specific areas on Earth after sunset, potentially supporting emergency operations and extending electricity generation at solar farms.
The company received FCC authorization in July for its first experimental satellite, Eärendil-1, which will use an 18-meter reflector to test the concept from orbit.
The October demonstration used ground-based lighting. No orbital mirror has yet demonstrated the proposed capability.
Anthropic files S-1 with the SEC for proposed initial public offering \ Anthropic anthropic.com/news/s1-sec











